Bulk Pharmaceutical API Sources for SKLICE

Bulk Pharmaceutical API Sources for SKLICE

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		I8898_SIGMA
MP Biomedicals		196009
MolPort		MolPort-006-394-715
ABI Chem		AC1N7O27
ChemMol		49423574
Chembase.cn		72880
Chembase.cn		106030

Last updated: July 28, 2025

lk Active Pharmaceutical Ingredient (API) Sources for Sklice

Introduction
Sklice (ivermectin lotion 0.65%) is a topical medication approved by the FDA primarily for the treatment of head lice. As a branded formulation, it relies on the active pharmaceutical ingredient (API) ivermectin, a broad-spectrum antiparasitic agent. The sourcing of bulk API is critical to ensuring the quality, safety, and efficacy of Sklice. This report examines the key sources of ivermectin API used for manufacturing Sklice, exploring supply chain dynamics, regulatory considerations, and industry trends that influence sourcing decisions.

Overview of Ivermectin API for Sklice
Ivermectin is a macrocyclic lactone derived from Streptomyces avermitilis bacteria. For Sklice, the API is processed into a 0.65% lotion, requiring high-purity ivermectin to meet stringent pharmaceutical standards. The API must conform to pharmacopeial specifications, including potency, purity, and absence of contaminants.

Major API Manufacturers Supplying Ivermectin

1. Merck & Co. (MSD)

Merck historically developed ivermectin as an antiparasitic for human and veterinary use. Although primarily a consumer-facing pharmaceutical company, Merck's involvement in ivermectin production for global health programs, notably for tropical diseases, has influenced the API's availability. Merck supplies ivermectin to various manufacturers through licensing arrangements, often under compliance with strict quality controls.

2. Sun Pharmaceutical Industries Ltd.

Sun Pharma is a leading API manufacturer and exporter. It produces ivermectin complying with international standards, including USP and BP monographs. Their facilities are WHO-GMP certified, and they supply ivermectin API for various indications, including topical formulations like Sklice. The company's large-scale manufacturing capabilities enable consistent supply for global markets.

3. M/S Hetero Labs Ltd.

Hetero Labs has expanded its portfolio to include ivermectin API, with facilities approved by the US FDA, EMA, and other regulatory bodies. The company supplies bulk ivermectin API to finished dosage manufacturers, with a focus on compliance and controlled batch-to-batch consistency.

4. Biocon

Biocon, an Indian biopharmaceutical leader, produces ivermectin API primarily for domestic and select export markets. Their manufacturing practices meet international standards, and they supply to several global pharmaceutical companies for both oral and topical formulations.

5. Aurobindo Pharma

Aurobindo is a prominent API producer with a focus on quality and scalability. They manufacture ivermectin API suitable for human use at pharmaceutical-grade levels, adhering to regulatory requirements essential for topical products like Sklice.

Emerging and Specialized API Suppliers

6. Lekim (Russia)

Lekim produces ivermectin API for regional markets, with increasing interest for global supply chains. Their manufacturing facilities are GMP certified, and they adhere to pharmacopoeial standards, positioning them as potential alternative sources for ivermectin API.

7. GoldTech LLC (India)

A newer entrant to API manufacturing, GoldTech offers high-quality ivermectin with GMP certification, emphasizing cost-effective bulk supplies. Their production capacity and regulatory compliance make them a notable emerging supplier.

Supply Chain Dynamics and Sourcing Strategies
The global API supply chain for ivermectin is concentrated mainly in India and China, with key players operating under stringent Good Manufacturing Practices (GMP). The supply chain faces challenges including capacity constraints, geopolitical considerations, and quality assurance.

Manufacturers of Sklice typically source ivermectin API from multiple suppliers to mitigate risk, ensure quality consistency, and respond to demand fluctuations. Stringent quality control measures, such as batch testing and certification under pharmacopeias, are critical due to the medication's topical application, where impurities could cause adverse skin reactions.

Regulatory Considerations for API Sourcing
Regulatory compliance governs API sourcing decisions. Manufacturers must ensure that the API is manufactured under GMP conditions, with batch-specific COAs (Certificates of Analysis) and adherence to international pharmacopoeias (USP, EP, BP, etc.). For products like Sklice, which are directly applied to the skin, the API must meet high purity thresholds, including limits on residual solvents, heavy metals, and microbial contamination.

Sourcing from certified suppliers also involves validation of manufacturing processes, periodic audits, and ongoing quality monitoring to maintain regulatory approval across different markets, especially in the US, EU, and emerging markets.

Industry Trends Affecting API Sourcing for Sklice
Recent industry trends affecting ivermectin API sourcing include:

• Increased demand due to COVID-19: Although ivermectin gained attention as a potential COVID-19 therapeutic, regulatory authorities remain cautious, and manufacturers continue to prioritize quality supply chains for approved indications.
• Supply chain resilience: The COVID-19 pandemic highlighted vulnerabilities in global supply chains, prompting pharmaceutical companies to diversify their API sources and establish local manufacturing capabilities.
• Regulatory harmonization: Efforts by authorities like WHO, US FDA, and EMA to standardize API quality specifications streamline sourcing but also demand higher compliance standards.
• Cost optimization: Indian and Chinese manufacturers offer cost-competitive APIs, prompting global companies to develop strategic partnerships or establish local supplier relationships.

Conclusion
The primary sources of ivermectin API for Sklice are well-established Indian and international manufacturers with GMP-certified facilities, such as Sun Pharma, Hetero Labs, Aurobindo Pharma, and Biocon. Ensuring a diversified supply chain, compliance with regulatory standards, and rigorous quality assurance are critical to the successful manufacturing of Sklice. Emerging suppliers from Russia and newer Indian manufacturers are poised to influence the API landscape further. As global demand and regulatory environments evolve, sourcing strategies must adapt to maintain supply continuity, quality, and cost-effectiveness.

---

Key Takeaways

• Indian API manufacturers (Sun Pharma, Aurobindo, Hetero) dominate ivermectin API supply for Sklice, supported by robust GMP compliance.
• Diversification of suppliers—including emerging markets—mitigates supply chain risks.
• Regulatory adherence, including pharmacopeial compliance and quality certifications, is non-negotiable for topical APIs.
• Industry trends favor increased local manufacturing and diversified sourcing to ensure resilience against global disruptions.
• The ongoing demand for ivermectin emphasizes the importance of quality and regulatory compliance in API procurement strategies.

---

FAQs

1. Who are the leading API manufacturers for ivermectin used in Sklice?
The leading manufacturers include Sun Pharmaceutical Industries, Hetero Labs, Aurobindo Pharma, and Biocon, primarily based in India, with additional providers like Lekim (Russia) gaining prominence.

2. What quality standards must ivermectin API meet for topical formulations like Sklice?
The API must adhere to pharmacopeial standards such as USP or EP, ensuring high purity, potency, and low levels of residual solvents, heavy metals, and microbial contaminants, especially for topical use.

3. How does supply chain diversification benefit Sklice manufacturing?
Diversification reduces reliance on a single supplier, mitigates risks from geopolitical or supply disruptions, and enhances the stability of API availability.

4. Are there regulatory concerns related to sourcing ivermectin API internationally?
Yes, API suppliers must comply with GMP standards, and manufacturers must obtain appropriate certifications and conduct supplier audits to meet global regulatory requirements.

5. How might industry trends influence future API sourcing for Sklice?
Growing demand, supply chain resilience efforts, and regulatory harmonization are likely to drive increased local manufacturing, new supplier emergence, and improved quality standards.

References
[1] World Health Organization (WHO). Guidelines on good pharmacovigilance practices. 2020.
[2] U.S. Pharmacopeia (USP). USP Monograph on Ivermectin. 2022.
[3] Indian Pharmacopoeia Commission. Pharmacopoeial standards for ivermectin. 2021.
[4] Pharmaceutical Technology. API sourcing trends post-pandemic. 2022.
[5] European Medicines Agency (EMA). Guidelines for good manufacturing practices. 2021.